

Katherine A Lyseng-Williamson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4839272/publications.pdf>

Version: 2024-02-01

243
papers

3,456
citations

159525
30
h-index

168321
53
g-index

264
all docs

264
docs citations

264
times ranked

4997
citing authors

#	ARTICLE	IF	CITATIONS
1	Liposomal Amphotericin B. <i>Drugs</i> , 2009, 69, 361-392.	4.9	259
2	Docetaxel. <i>Drugs</i> , 2005, 65, 2513-2531.	4.9	184
3	Ferric Carboxymaltose. <i>Drugs</i> , 2009, 69, 739-756.	4.9	169
4	Meropenem. <i>Drugs</i> , 2008, 68, 803-838.	4.9	165
5	Micronised Purified Flavonoid Fraction. <i>Drugs</i> , 2003, 63, 71-100.	4.9	143
6	Levetiracetam: a review of its use in epilepsy. <i>Drugs</i> , 2011, 71, 489-514.	4.9	141
7	Miglustat: A Review of Its Use in Niemann-Pick Disease Type C. <i>Drugs</i> , 2014, 74, 61-74.	4.9	103
8	Idebenone: A Review in Leber's Hereditary Optic Neuropathy. <i>Drugs</i> , 2016, 76, 805-813.	4.9	93
9	Moxonidine. <i>Drugs</i> , 2006, 66, 477-496.	4.9	77
10	Tenofovir Disoproxil Fumarate. <i>Drugs</i> , 2005, 65, 413-432.	4.9	74
11	Sitagliptin. <i>Drugs</i> , 2007, 67, 587-597.	4.9	69
12	Clopidogrel. <i>Drugs</i> , 2007, 67, 613-646.	4.9	67
13	Pegloticase. <i>Drugs</i> , 2011, 71, 2179-2192.	4.9	63
14	Esomeprazole. <i>Drugs</i> , 2008, 68, 1571-1607.	4.9	62
15	Pranlukast. <i>Drugs</i> , 2003, 63, 991-1019.	4.9	58
16	Rimonabant. <i>Drugs</i> , 2006, 66, 2109-2119.	4.9	55
17	Zoledronic Acid. <i>Drugs</i> , 2008, 68, 507-534.	4.9	53
18	Tolcapone. <i>CNS Drugs</i> , 2005, 19, 165-184.	2.7	51

#	ARTICLE	IF	CITATIONS
19	Spotlight on Levetiracetam in Epilepsy. CNS Drugs, 2011, 25, 901-905.	2.7	51
20	Melatonin Prolonged Release. Drugs and Aging, 2012, 29, 911-923.	1.3	50
21	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. Clinical Drug Investigation, 2019, 39, 805-819.	1.1	47
22	Pregabalin. Drugs, 2008, 68, 2205-2223.	4.9	46
23	Extended-Release Methylphenidate (Ritalin?? LA*). Drugs, 2002, 62, 2251-2259.	4.9	40
24	Etanercept. Drugs, 2007, 67, 1211-1241.	4.9	40
25	Inhaled Salmeterol/Fluticasone Propionate Combination. Pharmacoeconomics, 2003, 21, 951-989.	1.7	39
26	Memantine. Pharmacoeconomics, 2005, 23, 193-206.	1.7	36
27	Varenicline. Pharmacoeconomics, 2010, 28, 231-254.	1.7	35
28	Insulin Lispro. Drugs, 2007, 67, 407-434.	4.9	34
29	Adalimumab. BioDrugs, 2007, 21, 125-132.	2.2	33
30	Recombinant Factor VIIa (Eptacog Alfa). Pharmacoeconomics, 2007, 25, 1007-1029.	1.7	33
31	Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies. BioDrugs, 2013, 27, 533-540.	2.2	31
32	Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B. Drugs, 2017, 77, 97-106.	4.9	30
33	Trastuzumab. Pharmacoeconomics, 2008, 26, 699-719.	1.7	29
34	Aripiprazole. CNS Drugs, 2004, 18, 367-376.	2.7	28
35	Degarelix. Drugs, 2009, 69, 1967-1976.	4.9	28
36	Spotlight on Bevacizumab in Advanced Colorectal Cancer, Breast Cancer, and Non-Small Cell Lung Cancer. BioDrugs, 2006, 20, 193-195.	2.2	26

#	ARTICLE	IF	CITATIONS
37	Oral Bepotastine. <i>Drugs</i> , 2010, 70, 1579-1591.	4.9	26
38	Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A) Tj ETQq0 0 0 rgBT/Overlock,10 Tf 50 7	2.2	25
39	Inhaled Salmeterol/Fluticasone Propionate. <i>Drugs</i> , 2005, 65, 1715-1734.	4.9	24
40	Erlotinib. <i>Pharmacoeconomics</i> , 2010, 28, 75-92.	1.7	24
41	Lenalidomide. <i>Drugs</i> , 2011, 71, 625-649.	4.9	24
42	Atorvastatin. <i>Pharmacoeconomics</i> , 2007, 25, 1031-1053.	1.7	22
43	Intravenous Busulfan. <i>Paediatric Drugs</i> , 2007, 9, 271-278.	1.3	22
44	Imidapril. <i>Drugs</i> , 2007, 67, 1359-1378.	4.9	22
45	Subcutaneous Recombinant Interferon- β -1a (Rebif $\text{\textcircled{R}}$). <i>Drugs</i> , 2011, 71, 1865-1891.	4.9	22
46	Posaconazole. <i>Pharmacoeconomics</i> , 2011, 29, 251-268.	1.7	21
47	Infliximab. <i>Pharmacoeconomics</i> , 2004, 22, 107-132.	1.7	20
48	Romiplostim. <i>Drugs</i> , 2009, 69, 307-317.	4.9	20
49	Buprenorphine 5, 10 and 20 μ g/h Transdermal Patch: A Guide to Its Use in Chronic Non-Malignant Pain. <i>CNS Drugs</i> , 2012, 26, 367-373.	2.7	20
50	Lumiracoxib. <i>Drugs</i> , 2004, 64, 2237-2246.	4.9	18
51	Aripiprazole. <i>CNS Drugs</i> , 2008, 22, 807-813.	2.7	18
52	Ginkgo biloba extract EGb 761 $\text{\textcircled{R}}$ in the symptomatic treatment of mild-to-moderate dementia: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 358-366.	0.3	18
53	Etanercept. <i>Pharmacoeconomics</i> , 2004, 22, 1071-1095.	1.7	17
54	Bosentan. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 189-208.	1.0	17

#	ARTICLE	IF	CITATIONS
55	Tadalafil. <i>Drugs</i> , 2010, 70, 479-488.	4.9	17
56	Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. <i>Drugs</i> , 2018, 78, 941-950.	4.9	17
57	Clopidogrel. <i>Pharmacoeconomics</i> , 2006, 24, 709-726.	1.7	16
58	Fentanyl Pectin Nasal Spray. <i>CNS Drugs</i> , 2011, 25, 511-522.	2.7	16
59	Subcutaneous Recombinant Interferon- γ -1a (Rebif [®]). <i>Drugs</i> , 2005, 65, 1295-1312.	4.9	15
60	Ziconotide. <i>CNS Drugs</i> , 2006, 20, 331-338.	2.7	15
61	Vincristine Sulfate Liposome Injection. <i>BioDrugs</i> , 2013, 27, 69-74.	2.2	14
62	DTaP-IPV-Hep B-Hib vaccine (Hexyon [®] /Hexacima [®]): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 329-335.	0.3	14
63	Spotlight on Topiramate in Epilepsy ¹ . <i>CNS Drugs</i> , 2008, 22, 171-174.	2.7	13
64	Oromucosal Midazolam: A Guide to Its Use in Paediatric Patients with Prolonged Acute Convulsive Seizures. <i>CNS Drugs</i> , 2012, 26, 893-897.	2.7	13
65	Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares. <i>BioDrugs</i> , 2013, 27, 401-406.	2.2	13
66	Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 49-56.	1.0	12
67	Nelarabine. <i>Drugs</i> , 2008, 68, 439-447.	4.9	11
68	Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria. <i>BioDrugs</i> , 2012, 26, 125-130.	2.2	11
69	Spotlight on Subcutaneous Recombinant Interferon- γ -1a (Rebif [®]) in Relapsing-Remitting Multiple Sclerosis ¹ . <i>BioDrugs</i> , 2005, 19, 323-325.	2.2	10
70	Zoledronic Acid. <i>Drugs</i> , 2008, 68, 2661-2682.	4.9	10
71	Nanofiltered Human C1 Inhibitor Concentrate (Cinryze [®]). <i>BioDrugs</i> , 2011, 25, 317-327.	2.2	9
72	Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU. <i>BioDrugs</i> , 2013, 27, 275-279.	2.2	9

#	ARTICLE	IF	CITATIONS
73	Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 463-469.	0.3	9
74	Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 67-71.	3.3	8
75	Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 401-410.	0.3	8
76	Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 110-118.	0.3	8
77	Midazolam oral solution (Ozalin®): a profile of its use for procedural sedation or premedication before anaesthesia in children. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 255-262.	0.3	8
78	Budesonide/Formoterol Pressurized Metered-Dose Inhaler. <i>Drugs</i> , 2008, 68, 1855-1864.	4.9	7
79	Telavancin. <i>Drugs</i> , 2009, 69, 2607-2620.	4.9	7
80	Vismodegib. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 61-64.	3.3	7
81	Regorafenib: A Guide to Its Use in Advanced Gastrointestinal Stromal Tumor (GIST) After Failure of Imatinib and Sunitinib. <i>BioDrugs</i> , 2013, 27, 525-531.	2.2	7
82	Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 336-341.	0.3	7
83	Spotlight on Galantamine in Alzheimer's Disease*. <i>Disease Management and Health Outcomes</i> , 2003, 11, 125-128.	0.3	6
84	Budesonide/Formoterol Pressurized Metered-Dose Inhaler. <i>Drugs</i> , 2009, 69, 1459-1470.	4.9	6
85	Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation. <i>CNS Drugs</i> , 2010, 24, 797-800.	2.7	6
86	Erlotinib. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 57-62.	1.6	6
87	Everolimus: A Guide to Its Use in Liver Transplantation. <i>BioDrugs</i> , 2013, 27, 407-411.	2.2	6
88	Cationorm® (cationic emulsion eye drops) in dry eye disease: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 317-322.	0.3	6
89	K-haler® breath-triggered inhaler: a profile of the properties of the device. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 315-320.	0.3	6
90	Cetuximab. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 317-322.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer. <i>Drugs and Aging</i> , 2012, 29, 243-248.	1.3	5
92	17 β -Hydroxyprogesterone Caproate (Makena [®]). <i>Clinical Drug Investigation</i> , 2013, 33, 223-227.	1.1	5
93	Loteprednol Etabonate Ophthalmic Gel 0.5%: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery. <i>Drugs</i> , 2013, 73, 949-958.	4.9	5
94	Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 8-15.	0.3	5
95	Fexinidazole in human African trypanosomiasis: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 529-535.	0.3	5
96	Management of Metastatic Colorectal Cancer. <i>Disease Management and Health Outcomes</i> , 2005, 13, 137-149.	0.3	4
97	Niacin Extended Release (ER)/Simvastatin (Simcor [®]). <i>Drugs in R and D</i> , 2010, 10, 253-260.	1.1	4
98	Fondaparinux. <i>Pharmacoeconomics</i> , 2010, 28, 687-698.	1.7	4
99	Sublingual five-grass pollen tablets (Oralair [®]): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 200-208.	0.3	4
100	Interferon β -1b in chronic granulomatous disease and severe malignant osteopetrosis: a guide to its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 213-220.	0.3	4
101	House dust mite sublingual tablets (Actair [®]): a guide to their use as allergy immunotherapy for house dust mite-induced allergic rhinitis. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 219-225.	0.3	4
102	<i>Bifidobacterium infantis</i> 35624 as a probiotic dietary supplement: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 368-374.	0.3	4
103	Torsemide Prolonged Release. <i>Drugs</i> , 2009, 69, 1363-1372.	4.9	3
104	Rasagiline: A Guide to Its Use in Parkinson's Disease. <i>CNS Drugs</i> , 2012, 26, 781-785.	2.7	3
105	Ticagrelor: a review of its cost effectiveness in the management of acute coronary syndromes. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 379-386.	0.3	3
106	Vemurafenib. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 65-69.	3.3	3
107	Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix [®]): A Guide to Its Two-Dose Schedule in Girls Aged 9-14 Years in the EU. <i>Paediatric Drugs</i> , 2014, 16, 247-253.	1.3	3
108	Tiotropium Respimat [®] Soft Mist [®] inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 39-44.	0.3	3

#	ARTICLE	IF	CITATIONS
109	Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. <i>BioDrugs</i> , 2015, 29, 399-406.	2.2	3
110	Clotiapine in schizophrenia: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 365-371.	0.3	3
111	Daclatasvir in hepatitis C virus infection: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 42-49.	0.3	3
112	Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 47-53.	0.3	3
113	Aprotinin in adults at high risk of major blood loss during isolated CABG with cardiopulmonary bypass: a profile of its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 1-11.	0.3	3
114	DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa [®] , ϕ): A Guide to Its Use in Infants. <i>Paediatric Drugs</i> , 2012, 14, 337-343.	1.3	3
115	Bivalirudin. <i>Pharmacoeconomics</i> , 2011, 29, 343-359.	1.7	3
116	Spotlight on Lenalidomide in Relapsed or Refractory Multiple Myeloma. <i>BioDrugs</i> , 2011, 25, 333-337.	2.2	2
117	OnabotulinumtoxinA (BOTOX [®]): A Guide to Its Use in Preventing Headaches in Adults with Chronic Migraine. <i>CNS Drugs</i> , 2012, 26, 717-723.	2.7	2
118	Ferumoxytol: a guide to its use in iron deficiency anaemia in adults with chronic kidney disease in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 223-227.	0.3	2
119	Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 161-165.	0.3	2
120	Once-Daily Memantine. <i>Drugs and Aging</i> , 2013, 30, 51-58.	1.3	2
121	Formoterol/budesonide pressurized metered-dose inhaler: a guide to its use in chronic obstructive pulmonary disease. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 269-275.	0.3	2
122	Cobicistat: a guide to its use as a pharmacokinetic enhancer of atazanavir and darunavir in HIV-1 infection. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 309-315.	0.3	2
123	Sodium oxybate: a guide to its use in narcolepsy. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 282-289.	0.3	2
124	Standardized quality house dust mite sublingual tablets (Acarizax [®]): a guide to their use as sublingual allergy immunotherapy in Europe. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 502-509.	0.3	2
125	Collagenase Clostridium histolyticum in Dupuytren's contracture: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 131-137.	0.3	2
126	Buprenorphine oral lyophilisate (Espranor [®]) in the substitution treatment of opioid dependence: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 241-248.	0.3	2

#	ARTICLE	IF	CITATIONS
127	Deflazacort in Duchenne muscular dystrophy: a profile of its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 16-22.	0.3	2
128	Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer. <i>Drugs</i> , 2020, 80, 1723-1730.	4.9	2
129	Intravenous Busulfan: A Guide to Its Use as Conditioning Treatment before Transplantation of Haematopoietic Progenitor Cells. <i>Clinical Drug Investigation</i> , 2012, 32, 641-648.	1.1	2
130	Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US. <i>Paediatric Drugs</i> , 2012, 14, 345-350.	1.3	2
131	Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-4.	0.3	2
132	Miocamycin is an effective option in the treatment of various bacterial infections. <i>Drugs and Therapy Perspectives</i> , 2006, 22, 1-6.	0.3	1
133	Linagliptin: a guide to its use in type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-5.	0.3	1
134	Prasugrel: A Guide to Its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the US. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 207-216.	1.0	1
135	Ipilimumab: A Guide to Its Use in Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 349-354.	3.3	1
136	Aclidinium: a guide to its use in chronic obstructive pulmonary disease in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 34-39.	0.3	1
137	Azithromycin 1.5% ophthalmic solution: a guide to its use in purulent bacterial conjunctivitis and trachomatous conjunctivitis. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 97-101.	0.3	1
138	Nomegestrol acetate/estradiol: a guide to its use in oral contraception. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 1-6.	0.3	1
139	Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 155-160.	0.3	1
140	Nanofiltered human C1 inhibitor concentrate (Cinryze®): a guide to its use in hereditary angioedema in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 260-267.	0.3	1
141	Oral olanzapine: a guide to its use in adults with schizophrenia or bipolar I disorder. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 291-296.	0.3	1
142	Saxagliptin: a guide to its use in type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 92-99.	0.3	1
143	Ipilimumab: a guide to its use in advanced melanoma in the EU. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 124-129.	0.3	1
144	Peginterferon beta-1a in relapsing/remitting multiple sclerosis: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 190-195.	0.3	1

#	ARTICLE	IF	CITATIONS
145	Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 323-329.	0.3	1
146	Oxycodone prolonged release: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 363-368.	0.3	1
147	9-Valent human papillomavirus recombinant vaccine (Gardasil® 9): a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 414-421.	0.3	1
148	Human α 1-proteinase inhibitor (Respreeza®) in α 1-antitrypsin deficiency emphysema: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 422-427.	0.3	1
149	Ferric maltol in iron deficiency anaemia in patients with inflammatory bowel disease: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 226-231.	0.3	1
150	Vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 265-275.	0.3	1
151	Apremilast in psoriasis: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 361-367.	0.3	1
152	Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 405-412.	0.3	1
153	Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 263-270.	0.3	1
154	Elagolix in endometriosis-related pain: a profile of its use as approved in the USA. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 110-118.	0.3	1
155	Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 160-166.	0.3	1
156	<i>Drugs and Therapy Perspectives</i> , 2020, 36, 539-546.	0.3	1
157	Methadone is an option to treat cancer pain in carefully selected patients. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 502-508.	0.3	1
158	Choose treatment for restless legs syndrome based on patient and drug characteristics. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 435-439.	0.3	1
159	A/H5N1 Prepandemic Influenza Vaccine (Vepacel®): A Guide to Its Use. <i>BioDrugs</i> , 2012, 26, 425-430.	2.2	1
160	Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 5-9.	0.3	1
161	Polyphenon E 10% ointment: a guide to its use in the treatment of external genital and perianal warts. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 6-9.	0.3	1
162	Oral Paricalcitol. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2006, 5, 319-325.	1.8	0

#	ARTICLE	IF	CITATIONS
163	Ambrisentan: a guide to its use in pulmonary arterial hypertension. <i>Drugs and Therapy Perspectives</i> , 2009, 25, 1-5.	0.3	0
164	Ambrisentan: a guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 1-8.	0.3	0
165	Pirfenidone: a guide to its use in idiopathic pulmonary fibrosis. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 10-13.	0.3	0
166	Degarelix: a guide to its use in advanced prostate cancer. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 6-10.	0.3	0
167	Ofatumumab: a guide to its use in chronic lymphocytic leukaemia. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 6-9.	0.3	0
168	AS04-adjuvanted human papillomavirus types 16/18 vaccine (Cervarix®): a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-6.	0.3	0
169	Fidaxomicin: a guide to its use in <i>Clostridium difficile</i> infection. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-5.	0.3	0
170	Fentanyl pectin nasal spray: a guide to its use in breakthrough pain in opioid-tolerant adults with cancer. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 6-10.	0.3	0
171	Fixed-dose acetylsalicylic acid/esomeprazole: a guide to its use to prevent cardiovascular events and reduce peptic ulcer risk. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 10-14.	0.3	0
172	Dexmedetomidine: a guide to its use for sedation in the intensive care unit in the EU. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-5.	0.3	0
173	Rotigotine transdermal patch: a guide to its use in Parkinson's disease and restless leg syndrome. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 57-63.	0.3	0
174	Melatonin prolonged release: a guide to its use in the treatment of insomnia in patients aged ≥55 years. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 125-129.	0.3	0
175	Crizotinib: a guide to its use in previously treated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 64-68.	0.3	0
176	Rotavirus vaccine RIX4414 (Rotarix®): a guide to its use in preventing rotavirus gastroenteritis in the EU. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 130-134.	0.3	0
177	Inhaled glycopyrronium bromide: a guide to its use in moderate to severe chronic obstructive pulmonary disease. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 367-372.	0.3	0
178	Bemiparin: a guide to its use in thromboprophylaxis and the treatment of deep vein thrombosis. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 27-33.	0.3	0
179	News from the 41st European Symposium on Clinical Pharmacy, 28-31 October 2012, Barcelona. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 52-56.	0.3	0
180	Halobetasol propionate 0.05 % cream: a guide to its use in the treatment of plaque psoriasis. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 102-107.	0.3	0

#	ARTICLE	IF	CITATIONS
181	Dapagliflozin: a guide to its use in type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 194-199.	0.3	0
182	Perampanel: a guide to its use in partial-onset seizures. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 189-193.	0.3	0
183	Lorcaserin: a guide to its use in chronic weight management. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 303-308.	0.3	0
184	Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 253-259.	0.3	0
185	Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 268-274.	0.3	0
186	Paliperidone extended release: a guide to its use in schizophrenia in adolescents aged ≥15 years. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 380-385.	0.3	0
187	Lubiprostone: a guide to its use in chronic idiopathic constipation in the UK. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 375-379.	0.3	0
188	Etravirine: a guide to its use in treatment-experienced adults with HIV-1 infection. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 1-9.	0.3	0
189	News from the 42nd European Symposium on Clinical Pharmacy, 16–18 October 2013, Prague. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 26-32.	0.3	0
190	Pregabalin: a guide to its use in fibromyalgia, neuropathic pain and generalized anxiety disorder. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 75-84.	0.3	0
191	Desloratadine: a guide to its use in allergic disorders. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 35-41.	0.3	0
192	Linaclotide: a guide to its use in irritable bowel syndrome with constipation in the EU. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 342-347.	0.3	0
193	Ingenol mebutate gel: a guide to its use in actinic keratosis in the EU. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 155-160.	0.3	0
194	Clozapine oral suspension (Versaclozâ, ¢): a guide to its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 193-199.	0.3	0
195	Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 231-240.	0.3	0
196	Aclidinium bromide/formoterol fumarate dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 183-189.	0.3	0
197	Azelastine hydrochloride/fluticasone propionate combined in a single nasal spray: a guide to its use in allergic rhinitis. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 425-432.	0.3	0
198	News from the 43rd European Symposium on Clinical Pharmacy, 22–24 October 2014, Copenhagen. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 102-106.	0.3	0

#	ARTICLE	IF	CITATIONS
199	Vortioxetine in major depressive disorder: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 221-228.	0.3	0
200	Mirabegron: a guide to its use in overactive bladder syndrome in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 107-111.	0.3	0
201	Trazodone prolonged release: a guide to its use in depression. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 137-142.	0.3	0
202	Fulvestrant in postmenopausal women with locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy: a guide. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 323-328.	0.3	0
203	Pazopanib in advanced renal cell carcinoma: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 372-377.	0.3	0
204	Delamanid in multidrug-resistant tuberculosis: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 378-384.	0.3	0
205	Ivacaftor: a guide to its use in cystic fibrosis. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 17-22.	0.3	0
206	Imatinib: a guide to its use as adjuvant therapy for gastrointestinal stromal tumour (GIST) in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 45-51.	0.3	0
207	Macitentan: a guide to its use in the treatment of pulmonary arterial hypertension in adults of WHO functional class II or III in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 83-88.	0.3	0
208	Ustekinumab in adolescents with moderate to severe plaque psoriasis: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 138-142.	0.3	0
209	Umeclidinium/vilanterol dry-powder inhaler in chronic obstructive pulmonary disease: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 276-281.	0.3	0
210	Levofloxacin hydrate 1.5% ophthalmic solution in external ocular infections and intraocular surgery: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 449-455.	0.3	0
211	Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 369-380.	0.3	0
212	Recombinant von Willebrand factor (vonicog alfa) in von Willebrand disease: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 456-462.	0.3	0
213	Eribulin mesylate in previously treated patients with advanced liposarcoma: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 510-514.	0.3	0
214	News from the 44th ESCP Symposium on Clinical Pharmacy, 28-30 October 2015, Lisbon. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 30-34.	0.3	0
215	Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 50-59.	0.3	0
216	Icosapent ethyl in hypertriglyceridaemia: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 91-97.	0.3	0

#	ARTICLE	IF	CITATIONS
217	Pylera® (bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride) in the eradication of Helicobacter pylori infection: a profile of its use in Europe. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 311-320.	0.3	0
218	Vorapaxar in the long-term secondary prevention of atherothrombotic events: a profile of its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 254-259.	0.3	0
219	Pixantrone in relapsed or refractory aggressive non-Hodgkin's lymphoma: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 160-166.	0.3	0
220	Fluticasone furoate/vilanterol dry-powder inhaler in asthma: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 153-159.	0.3	0
221	Bilastine in symptomatic allergic rhinoconjunctivitis and urticaria: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 102-109.	0.3	0
222	Uridine triacetate in the emergency treatment of fluorouracil or capecitabine overdose or toxicity: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 56-61.	0.3	0
223	Nivolumab in previously treated patients with advanced renal cell carcinoma: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 167-173.	0.3	0
224	Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 8-15.	0.3	0
225	Sufentanil sublingual tablet system in the treatment of acute postoperative pain in adults: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 409-417.	0.3	0
226	Decitabine in newly diagnosed acute myeloid leukaemia: a profile of its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 505-514.	0.3	0
227	News from the 45th ESCP Symposium on Clinical Pharmacy, 4-6 October 2016, Oslo. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 72-76.	0.3	0
228	Poractant alfa in respiratory distress syndrome in preterm infants: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 455-462.	0.3	0
229	Hexaminolevullinate: a profile of its use with blue-light cystoscopy in the diagnosis of bladder cancer. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 463-472.	0.3	0
230	Reply-Letter to the Editor: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 194-195.	0.3	0
231	Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT®, [†]) in attention-deficit hyperactivity disorder in children aged 6-17 years: a profile of their use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 43-49.	0.3	0
232	SB4 (Benepali®; an etanercept biosimilar): a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 50-61.	0.3	0
233	Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 1-7.	0.3	0
234	Ambrisentan and tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 289-299.	0.3	0

#	ARTICLE	IF	CITATIONS
235	Zinc l-carnosine in gastric ulcers: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 463-469.	0.3	0
236	Omadacycline in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 305-314.	0.3	0
237	Encorafenib + binimetinib: a profile of their combined use in treating BRAF-mutated unresectable or metastatic melanoma. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 151-159.	0.3	0
238	Oxymetazoline 1% cream in erythema of rosacea: a profile of its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 7-12.	0.3	0
239	Rimegepant orally disintegrating tablets in the acute treatment of migraine: a profile of their use. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 547-552.	0.3	0
240	Ulipristal acetate: a guide to its use in uterine fibroids. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-4.	0.3	0
241	Fingolimod: a guide to its use in multiple sclerosis in the EU. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 6-11.	0.3	0
242	Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection. <i>Clinical Drug Investigation</i> , 2012, 32, 715-722.	1.1	0
243	Bilastine: a guide to its use in the treatment of symptomatic allergic rhinoconjunctivitis and urticaria. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 1-5.	0.3	0